Gentrack extended its slump.
The early childhood education group intends to re-domicile on the ASX.
Pathway back to coverage of Cxbladder product at least three years away, shares expected to sharply fall.
Analysts say it could cost the company between 5% to 10% of ebitda.
Analysts label unfavourable Medicare decision very material for diagnostics company.
China’s regulator re-registers Synlait Dunsandel plant for China infant formula exports.
Dairyworks and Talbot Forest Cheese on the block in order to pay down debt.
Company directors need to lead the charge on considering risks and rewards from generative AI revolution.
Management are cautiously optimistic sales will continue to improve, although Middle East still struggling.
The results reflect a challenging period for the kiwifruit industry.
